Summarized by Masters of Longevity from Longevity Technology.
Early human testing of a new Alzheimer's candidate: a concise article about safety and biological marker signals, and what readers can expect next.
Key Takeaways
- MNA-001 was well tolerated in early human testing with no major safety issues.
- Dose-dependent reductions in CSF and plasma soluble TREM2 showed MNA-001 target engagement.
- Repeated dosing shifted CSF markers toward patterns seen in younger individuals.
